Chemotactic disorders.
Clinical disorders of phagocyte chemotaxis have heterogeneous etiologies. The physiologic defect can involve adherence, the cytoskeleton, deformability, granule dysfunction, regulation of receptors, or a variety of soluble mediators. At present, successful clinical management depends on early and compulsive attention to infectious complications. A host of new immunomodulators (GM-CSF, gamma interferon, tumor necrosis factor, etc.), made available through recombinant gene technology, are now under study and may provide new and more effective means of treatment for these life-threatening disorders.
Brown
C C
CC
Bacterial Diseases Section, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Gallin
J I
JI
D002630:Chemotactic Factors / Q000097:blood; D002633:Chemotaxis; D006801:Humans; D007154:Immune System Diseases / Q000097:blood / Q000503:physiopathology* / Q000628:therapy; D008264:Macrophages; D009240:N-Formylmethionine Leucyl-Phenylalanine; D009369:Neoplasms / Q000276:immunology / Q000503:physiopathology; D010585:Phagocyte Bactericidal Dysfunction / Q000503:physiopathology
D002630:Chemotactic Factors; D009240:N-Formylmethionine Leucyl-Phenylalanine